SCHEMBL10133643

SCHEMBL10133643

O=C1NCc2cc(-c3ccc(Nc4ccc(C(=O)N5CCCCC5)nc4)c4nccn34)ccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 3/20 0.49
TYK2 P29597 3/20 0.40
TP53BP1 Q12888 2/20 0.39
GSK3B P49841 1/20 0.37
PIM1 P11309 1/20 0.34
MKNK1 Q9BUB5 3/20 0.34
EIF4E P06730 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
F9 P00740 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
MTOR P42345 1/20 0.34
PIK3CG P48736 1/20 0.34
CLK2 P49760 1/20 0.34
CLK3 P49761 1/20 0.34
DYRK1A Q13627 1/20 0.34
TBK1 Q9UHD2 1/20 0.33
MAPK14 Q16539 1/20 0.33
PTK6 Q13882 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14162483 0.92 MAPKAPK5 (0.58) MAPKAPK5TYK2GSK3BPIM1PIK3CD
SCHEMBL10133644 0.90 MAPKAPK5 (0.49) MAPKAPK5TYK2TP53BP1GSK3BMKNK1
SCHEMBL10133647 0.90 MAPKAPK5 (0.51) MAPKAPK5TYK2TP53BP1GSK3BPIK3CD
SCHEMBL10133621 0.86 MAPKAPK5 (0.55) MAPKAPK5GSK3BMKNK1F9PIK3CD
SCHEMBL10133598 0.85 MAPKAPK5 (0.47) MAPKAPK5TYK2PIM1CLK2CLK3
SCHEMBL10133626 0.84 MAPKAPK5 (0.54) MAPKAPK5TP53BP1GSK3BMKNK1MKNK2
SCHEMBL10133624 0.83 MAPKAPK5 (0.66) MAPKAPK5GSK3BMKNK1MKNK2PIK3CD
SCHEMBL1685144 0.83 MAPKAPK5 (0.47) MAPKAPK5TYK2TP53BP1GSK3BMKNK1
SCHEMBL14162498 0.82 MAPKAPK5 (0.57) MAPKAPK5TYK2GSK3BPIK3CDPIK3CA
SCHEMBL1685207 0.82 MAPKAPK5 (0.60) MAPKAPK5TYK2MKNK1MKNK2PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885TYK2 67/4885TP53BP1 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.